Changeflow GovPing Healthcare & Life Sciences CAREGEN Neutralizing Peptide Against SARS-CoV-2...
Routine Notice Added Final

CAREGEN Neutralizing Peptide Against SARS-CoV-2, 2026

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

CAREGEN CO, LTD. filed US patent application US20260109734A1 on April 23, 2026, for a peptide with neutralizing activity against SARS-CoV-2, with an earlier filing date of October 22, 2025 (Application No. 19365687). The peptide specifically recognizes SARS-CoV-2 proteins, and the application covers three composition types: preventing infection, treating infection, and detecting SARS-CoV-2. Inventors include Yong Ji CHUNG, Eun Mi KIM, Eung Ji LEE, Young Min LEE, Han A KANG, and Min Kyeong JEONG. This published application does not create direct compliance obligations for third parties; entities developing similar therapeutic peptides may wish to review for prior art implications.

“The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.

What changed

CAREGEN CO, LTD. filed a published patent application (US20260109734A1) with the USPTO covering a peptide that specifically recognizes SARS-CoV-2 proteins and compositions for preventing, treating, and detecting the virus. The application, filed October 22, 2025 and published April 23, 2026, names six inventors and carries CPC classifications C07K 7/04 and A61P 31/14. This published application does not create direct compliance obligations for third parties; however, entities developing similar therapeutic peptides or diagnostics targeting SARS-CoV-2 should review this publication as potential prior art and consider freedom-to-operate analysis for their own programs.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Application US20260109734A1 Kind: A1 Apr 23, 2026

Assignee

CAREGEN CO, LTD.

Inventors

Yong Ji CHUNG, Eun Mi KIM, Eung Ji LEE, Young Min LEE, Han A KANG, Min Kyeong JEONG

Abstract

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

CPC Classifications

C07K 7/04 A61P 31/14

Filing Date

2025-10-22

Application No.

19365687

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent filing Therapeutic peptide research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!